Duyuru • Apr 01
Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion. Green Cross Holdings Corporation (KOSE:A005250) acquired 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) for KRW 50.5 billion on March 31, 2026. A cash consideration of KRW 50.45 billion will be paid by Green Cross Holdings Corporation. As part of consideration, KRW 50.45 billion is paid towards common equity of GREEN CROSS WellBeing Corporation. The transaction will be financed through bank borrowing of KRW 50.45 billion.
Green Cross Holdings Corporation (KOSE:A005250) completed the acquisition of 22.08% stake in GREEN CROSS WellBeing Corporation (KOSDAQ:A234690) from GC Biopharma Corp. (KOSE:A006280) on March 31, 2026. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩13,730, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 8.9% over the past three years. Valuation Update With 7 Day Price Move • Jun 10
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩17,090, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.1% over the past three years. Duyuru • Feb 12
Green Cross Holdings Corporation, Annual General Meeting, Mar 26, 2025 Green Cross Holdings Corporation, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩300 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 07 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%). Duyuru • Jul 18
China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) agreed to acquire 77.35% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation (KOSE:A005250) for approximately KRW 270 billion. China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) agreed to acquire 77.35% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation (KOSE:A005250) for approximately KRW 270 billion on July 17, 2024. A cash consideration of KRW 268.06 billion will be paid by China Resources Boya Bio-pharmaceutical Group for 97,558,858 shares. For the period ending December 31, 2023, Green Cross Hk Holdings Limited reported total revenue of KRW 45.88 billion and net loss of KRW 3.1 billion. As of December 31, 2023, Green Cross Hk Holdings Limited reported total debt of KRW 43.32 billion, total assets of KRW 144.86 billion and total common equity of KRW 101.55 billion. Upcoming Dividend • Dec 20
Upcoming dividend of ₩300 per share at 1.9% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%). New Risk • Sep 11
New major risk - Revenue and earnings growth Earnings have declined by 4.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Dividend is not well covered by earnings and cash flows. Payout ratio: 253% Paying a dividend despite having no free cash flows. Earnings have declined by 4.8% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Reported Earnings • Mar 26
Full year 2022 earnings released: EPS: ₩727 (vs ₩1,222 in FY 2021) Full year 2022 results: EPS: ₩727 (down from ₩1,222 in FY 2021). Revenue: ₩2.08t (up 13% from FY 2021). Net income: ₩32.8b (down 41% from FY 2021). Profit margin: 1.6% (down from 3.0% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Dec 21
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • May 22
First quarter 2022 earnings released: ₩47.00 loss per share (vs ₩287 profit in 1Q 2021) First quarter 2022 results: ₩47.00 loss per share (down from ₩287 profit in 1Q 2021). Revenue: ₩502.4b (up 45% from 1Q 2021). Net loss: ₩1.95b (down 115% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 04 April 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%). Valuation Update With 7 Day Price Move • Aug 27
Investor sentiment improved over the past week After last week's 16% share price gain to ₩33,100, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 12% over the past three years. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improved over the past week After last week's 17% share price gain to ₩38,000, the stock trades at a trailing P/E ratio of 28.4x. Average trailing P/E is 53x in the Biotechs industry in South Korea. Total loss to shareholders of 3.8% over the past three years. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩36,850, the stock is trading at a trailing P/E ratio of 29.8x, down from the previous P/E ratio of 35.4x. This compares to an average P/E of 55x in the Biotechs industry in South Korea. Total return to shareholders over the past three years is a loss of 9.5%. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩45,300, the stock is trading at a trailing P/E ratio of 36.7x, down from the previous P/E ratio of 43.4x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 18%. Is New 90 Day High Low • Jan 04
New 90-day high: ₩53,600 The company is up 131% from its price of ₩23,250 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improved over the past week After last week's 19% share price gain to ₩41,500, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 28.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 10%. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩325 Per Share Will be paid on the 2nd of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.9% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.3%). Is New 90 Day High Low • Nov 04
New 90-day high: ₩35,000 The company is up 17% from its price of ₩29,850 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. Valuation Update With 7 Day Price Move • Nov 03
Market bids up stock over the past week After last week's 21% share price gain to ₩26,950, the stock is trading at a trailing P/E ratio of 40.1x, up from the previous P/E ratio of 33.1x. This compares to an average P/E of 65x in the Biotechs industry in South Korea. Total return to shareholders over the past three years is a loss of 26%. Is New 90 Day High Low • Oct 16
New 90-day low: ₩22,000 The company is down 9.0% from its price of ₩24,200 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Sep 24
New 90-day low: ₩22,350 The company is down 7.0% from its price of ₩23,950 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period. 
